News

New Study Suggests FebriDx® as a ‘Front Door Triage Tool’ in the Fight Against COVID-19

July 27, 2020

A new study in the Journal of Infection by Dr. Tristan Clark, et al. titled "Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19" identifies the FebriDx® test as a rapid, highly accurate, and affordable 'front door triage tool' to help healthcare providers differentiate viral from bacterial infection in patients with suspected COVID-19.

READ MORE
May 18, 2020

A New Algorithm for Sustainable Testing Capacity in Response to a Pandemic

A peer-reviewed article just published in the Annals of Medicine titled "Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic" describes an algorithm for sustainable testing capacity to efficiently evaluate patients in response to a pandemic.

READ MORE
April 7, 2020

UK NHS Could Save £89 Million and Further the Fight Against Antimicrobial Resistance

A new study just published in the Journal of Medical Economics found that the FebriDx® test could save the UK healthcare system up to £89 million a year on unnecessary antibiotics, and further its efforts in the fight against antimicrobial resistance.

READ MORE
March 26, 2020

Lumos Diagnostics Supports the Victorian Healthcare System by Providing FebriDx® for a Pilot Evaluation in the Triaging of Acute Respiratory Infection Patients

Lumos Diagnostics supports the Victorian healthcare system by providing FebriDx® for a pilot evaluation in the triaging of acute respiratory infection patients

READ MORE
February 5, 2020

Lumos Diagnostics Secures $15M in Series A Funding from Planet Innovation

Lumos Diagnostics, a point-of-care diagnostic test developer, manufacturer and marketer, secured U.S. $15 million in Series A funding from Planet Innovation, an Australia-based healthtech innovation and commercialization company.

READ MORE
December 17, 2019

FebriDx® Wins Biomarkers Award at 2019 UK Diagnostics Summit

Lumos Diagnostics received the Biomarkers Award at the recent 2019 UK Diagnostics Summit in Manchester, England for FebriDx®, a rapid POC test.

READ MORE
May 30, 2019

Lumos Diagnostics and RPS Diagnostics Merge to Create Full Service Development Company

Lumos Diagnostics, a previous spinoff from Australia-based Planet Innovation, and RPS Diagnostics, a Florida-based commercial diagnostic developer, manufacturer, and marketer of POC diagnostic tests, announced today that they have merged.

READ MORE

Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.